Clinical Trial Update: T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update on a T cell receptor therapy targeting MAGE-A3 in HLA-DP0401 positive metastatic cancer; study completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Cervical Cancer
• Melanoma
• Renal Cell Cancer
• Urothelial Cancer

Drugs mentioned

• T Cell Receptor Immunotherapy Targeting MAGE-A3 (TCR targeting MAGE-A3)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Cervical Cancer, Renal Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-03-29